破发股汇宇制药上半年亏损 2021上市即巅峰募24.7亿

Core Points - The company reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 453 million yuan, down 14.86% year-on-year, and a net loss of 80.72 million yuan compared to a profit of 65.21 million yuan in the same period last year [1][2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 48.07 million yuan, reflecting an increase of 11.56% year-on-year [1][2] - The net cash flow from operating activities was negative at -27.07 million yuan, a decline from 40.45 million yuan in the previous year [1][2] Financial Performance Overview - In 2021, the company had a revenue of 1.82 billion yuan, which decreased to 1.49 billion yuan in 2022, and further to 927 million yuan in 2023 [3] - The net profit attributable to shareholders for the same years was 446 million yuan in 2021, 249 million yuan in 2022, and 140 million yuan in 2023 [3] - The company achieved a revenue of 1.09 billion yuan in 2024, marking an 18.05% increase year-on-year, with a net profit of 325 million yuan, up 132.78% [4] Capital Raising and Use of Funds - The company raised a total of 2.472 billion yuan through its IPO, with a net amount of 2.361 billion yuan after deducting issuance costs [3] - The funds were intended for the construction of an EU-standard injection drug industrialization base, an innovative drug research institute, and to supplement working capital [3]